-
1 Comment
EyeGate Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 25.8% below its 200 day moving average.
From a valuation standpoint, the stock is 41.4% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 1893.6.
EyeGate Pharmaceuticals, Inc's total revenue rose by inf% to $12K since the same quarter in the previous year.
Its net income has increased by 100.0% to $0 since the same quarter in the previous year.
Finally, its free cash flow grew by 33.1% to $-2M since the same quarter in the previous year.
Based on the above factors, EyeGate Pharmaceuticals, Inc gets an overall score of 3/5.
Exchange | NASDAQ |
---|---|
CurrencyCode | USD |
Beta | 0.8 |
---|---|
Market Cap | None |
PE Ratio | None |
Target Price | None |
Dividend Yield | None |
The fund pursues its objective by investing, under normal circumstances, at least 80% of its net assets, including any borrowings for investment purposes, in investment grade fixed-income securities of corporate issuers. Corporate issuers may include corporate or other business entities in which a sovereign or governmental agency or entity may have, indirectly or directly, an interest, including a majority or greater ownership interest.
Here's how to backtest a trading strategy or backtest a portfolio for EYEG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025